Intercept Pharmaceuticals Stock Forecast, Price & News

+0.52 (+3.37 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.32 million shs
Average Volume1.03 million shs
Market Capitalization$528.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.32 out of 5 stars

Medical Sector

237th out of 1,350 stocks

Pharmaceutical Preparations Industry

113th out of 664 stocks

Analyst Opinion: 4.1Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

Is Intercept Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 11 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Intercept Pharmaceuticals?

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 8,500,000 shares, an increase of 67.7% from the July 29th total of 5,070,000 shares. Based on an average daily trading volume, of 897,200 shares, the days-to-cover ratio is presently 9.5 days. Currently, 31.2% of the shares of the company are short sold.
View Intercept Pharmaceuticals' Short Interest

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Intercept Pharmaceuticals

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Thursday, July, 29th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($1.24) by $0.91.
View Intercept Pharmaceuticals' earnings history

How has Intercept Pharmaceuticals' stock price been impacted by COVID-19?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ICPT shares have decreased by 79.5% and is now trading at $15.93.
View which stocks have been most impacted by COVID-19

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325 million-$340 million, compared to the consensus revenue estimate of $334.31 million.

What price target have analysts set for ICPT?

18 equities research analysts have issued twelve-month price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $10.00 to $67.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Jerome B. Durso, President, Chief Executive Officer & Director
  • Andrew Saik, Chief Financial Officer
  • M. Michelle Berrey, Chief Medical Officer
  • Linda M. Richardson, Chief Commercial Officer & Executive VP
  • Bryan Ball, Chief Quality Officer

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.16%), JPMorgan Chase & Co. (3.34%), Macquarie Group Ltd. (2.04%), Geode Capital Management LLC (1.47%), Goldman Sachs Group Inc. (1.20%) and Northern Trust Corp (0.90%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends for Intercept Pharmaceuticals

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, First Trust Advisors LP, Credit Suisse AG, Deutsche Bank AG, Ikarian Capital LLC, Goldman Sachs Group Inc., Rafferty Asset Management LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Intercept Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of Montreal Can, Susquehanna Fundamental Investments LLC, CM Management LLC, Campbell & CO Investment Adviser LLC, Russell Investments Group Ltd., Geode Capital Management LLC, and Credit Agricole S A.
View insider buying and selling activity for Intercept Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $15.93.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of $528.89 million and generates $312.69 million in revenue each year. The biopharmaceutical company earns $-274,880,000.00 in net income (profit) each year or ($8.34) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

Intercept Pharmaceuticals employs 498 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is

Where are Intercept Pharmaceuticals' headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at (646) 747-1000 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.